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The cholinesterase inhibitors (ChEIs)
donepezil, rivastigmine and galanta-
mine are standard treatment for mild-
to-moderate Alzheimer’s disease
(AD). Generally ChEIs are well toler-
ated [1], with a high retention rate
[2]. Common adverse events (nausea,
vomiting, diarrhoea, insomnia, mus-
cle cramps) are related to cholinergic
stimulation. The British National
Formulary also lists headache as a
side effect. Pooled donepezil clinical
trial data indicated 8%–13% of
patients experienced headache as an
adverse event (vs. 9% in placebo
group), which was considered med-
ication-related in about half the
patients [3]. To further investigate
this, an observational study to mea-
sure headache frequency in a
Cognitive Function Clinic population
prescribed ChEIs was undertaken.
Over a 5.5-year period (January
2001–June 2006 inclusive),
143 patients were commenced on
ChEIs (Table 1). In addition to
planned follow-up, patients and
caregivers were provided with a
telephone contact number in case of
adverse drug effects.
Two men (aged 70 and 56 years)
with mild-to-moderate AD (Mini-
Mental State Examination [MMSE]
scores 25/30 and 23/30, respectively)
complained of new daily headaches
with features of tension-type
headache within days of commencing
donepezil at a low dose (5 mg/day).
Headaches were continuous, global
in distribution, aching in nature and
unrelated to posture. One man noted
headache improvement on lying still;
he withdrew from treatment, with
cessation of headaches and associat-
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Table 1 Patient demographics and indications for ChEIs
n 143
M:F 68:75
Age at onset of ChEI treatment Range: 45–87 years
Duration of ChEI treatment Range: 1–66 months
Concurrent memantine treatment 7
Indications for ChEI treatment
AD+mixed AD/cerebrovascular 134
[Early-onset AD 78 (=58%)]
Vascular dementia/vascular cognitive impairment 2




ed nausea. After a drug-free interval
of 28 months, he had declined
(MMSE 22/30); galantamine was
commenced and titrated up to 24
mg/day without headache. In the
other patient, simple analgesia con-
trolled headache symptoms but he
was unable to increase to donepezil
10 mg/day. Neither patient had a his-
tory of prior primary headache disor-
der or current hypertension.
This pragmatic study suggests that
the frequency of ChEI-related
headache is very low (1.4%, 95%
CI=0.5%–3.3%). Hence, although
ChEIs may be responsible for
“headache induced by acute sub-
stance use or exposure” [4], in clini-
cal practice this is rare, seldom
requiring medication withdrawal.
Headache mechanism is obscure; it
may sometimes be causally related to
a cholinomimetic effect [3].
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